PHARMACISTS say the TGA decision to leave vardenafil and sildenafil S4 is a missed opportunity for them to help the 60% of Australian men aged 45 years plus with erectile dysfunction.
Last Sat 16 Sep the Australian College of Pharmacy held their "Pharmacy Controversies" half day CPD seminar in Brisbane.
In a presentation about managing risk in the treatment of erectile dysfunction, Dr Brett MacFarlane from the Australian College of Pharmacy informed the audience of the 15 Sep announcement of the interim decision by the TGA Scheduling Delegate to leave both vardenafil and sildenafil as S4, despite recent applications by their respective sponsors for down scheduling to S3.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Sep 17